Latest news

Gencove - Jun 01, 2022

Gencove and Element Biosciences, Inc. Partner to Offer Low-Pass Whole Genome Sequencing and Analysis with the AVITI™ System

NEW YORK – June 1, 2022 /GLOBENewswire/ – Gencove, pioneer of low-pass whole genome sequencing and analysis software, and Element Biosciences Inc., developer of the Element AVITI™ System, a new and disruptive DNA sequencing platform, today announced a joint marketing agreement to further reduce the cost and complexity of obtaining genomic information.

Read more >

Gencove - May 12, 2022

Gencove and NEOGEN® Launch InfiniSEEK™ — The First Whole Genome and Genotyping Sequencing Solution for Cattle Breeders

NEW YORK, N.Y., and LINCOLN, Neb., May 12, 2022 – Gencove, the leading low-pass whole genome sequencing and analysis software company along with NEOGEN® Corporation (NASDAQ: NEOG) today announced the launch of InfiniSEEK™, a revolutionary, cost-effective solution for whole genome sequencing and targeted SNP analysis from two trusted leaders in genomics.

Read more >

Gencove - Apr 13, 2022

TMG Selects Gencove’s Low-pass Whole Genome Sequencing and Analysis Platform as Part of Major Genomic Research and Development Initiative

NEW YORK, NY and Cambé, Brazil. – April 13, 2022 /GLOBENewswire/ – Gencove, the leading low-pass whole genome sequencing (LP-WGS) company and Tropical Improvement & Genetics (TMG), Brazil’s plant genomics company, today announced that TMG will be using Gencove’s LP-WGS platform to study soybeans as part of research and development investment.

Read more >

Gencove - Jan 26, 2022

BGI and Gencove Extend Agreement to Offer Low-Pass Whole Genome Sequencing and Analysis Services to Advance Global Health and Sustainability

Partnership delivers high-volume, cost-efficient, low-pass whole genome sequencing for human genetics and other applications.

NEW YORK and CAMBRIDGE, MA. – Jan. 10, 2022 /GLOBENewswire/ – Gencove, a pioneer of low-pass whole genome sequencing (LPWGS) analysis, and BGI Americas Corporation, US subsidiary of BGI Genomics Co. Ltd. (300676.SZ), one of the world’s leading multi-omics companies, today announced the extension of the subscription and joint marketing agreements. The partnership combines BGI"s sequencing services from proprietary DNBSEQ™ sequencing technology with Gencove’s analysis platform so that high-capacity, cost-efficient whole genome information can be made more accessible and actionable. Both companies are united by a common goal of providing genomic information for a healthier and more sustainable world.

Read more >

Gencove - Oct 26, 2021

Gencove Raises $10 Million to Meet the Global Demand for Accessible and Interpretable Whole Genome Sequencing at Scale

The company’s low-pass genome sequencing and bioinformatics platform provides a new way to power complete, accurate, and affordable genomic discovery

NEW YORK, NY — October 26, 2021 /PRNewswire/– Gencove, the leading low-pass genome sequencing platform company, today announced the successful close of a $10 million Series A investment bringing the company’s total financing to $16.2 million. The round was led by Lewis & Clark AgriFood with participation from new and existing investors including Spero Ventures, Techammer, Third Kind Venture Capital, and Version One Ventures. Funding will be used for further product development, commercial growth and to build out key business functions.

Read more >

Gencove - Mar 13, 2019

Gencove raises $3M investment led by Spero Ventures to expand genome sequencing platform

NEW YORK. – March 13, 2019 /PRNewswire/ -- Gencove, the leading low-pass genome sequencing platform, announced today a $3 million investment led by Spero Ventures. Alexandria Venture Investments and Burst Capital participated in the round, along with existing investors Third Kind Venture Capital and Version One Ventures. The funding will be used to develop new applications for agricultural markets as well as expand Gencove’s commercial operations in human genetics. Shripriya Mahesh, partner at Spero, will join Gencove’s board of directors.

Read more >